Apellis Pharmaceuticals

APLS

Market cap $3.13B

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 F, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2025 financial results on Thursday, October 30, 2025, at 8:30 a.m. ET.

Apellis Pharmaceuticals maintains a strong "Buy" rating for me, driven by robust SYFOVRE sales and recent EMPAVELI FDA approvals for rare kidney diseases. APLS is expanding SYFOVRE's potential with a phase 2 study combining it with siRNA APLS-3007, aiming to enhance efficacy in geographic atrophy. Upcoming phase 3 trials for EMPAVELI in FSGS and DGF represent significant pipeline catalysts, with potential first-to-market opportunities in large unmet needs.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Baird Global Healthcare Conference September 9, 2025 10:15 AM EDT Company Participants Cedric Francois - Co-Founder, President, CEO & Director Timothy Sullivan - CFO & Treasurer Conference Call Participants Colleen Hanley - Robert W. Baird & Co. Incorporated, Research Division Presentation Colleen Hanley Senior Research Analyst Right.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Cantor Global Healthcare Conference 2025 September 4, 2025 8:35 AM EDT Company Participants Cedric Francois - Co-Founder, President, CEO & Director Timothy Sullivan - CFO & Treasurer Conference Call Participants Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Presentation Steven Seedhouse MD & Biotechnology Analyst [Audio Gap] Would love to -- obviously, there's a lot going on at Apellis. It's an exciting time.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 8:45 AM EDT Company Participants Timothy Sullivan - CFO & Treasurer David Acheson - Executive Vice President of Commercial Conference Call Participants Derek Archila - Wells Fargo Securities, LLC, Research Division Presentation Derek Archila Senior Equity Analyst All right, everyone. I think we'll get started with our next session.

WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conferences:

Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli's New Approval

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Caroline R. Baumal - Chief Medical Officer Cedric Francois - Co-Founder, President, CEO & Director David L.

Apellis Pharmaceuticals has made pipeline progress and strengthened its balance sheet since I looked at this biopharma name earlier this year, warranting a fresh look at the stock. Recent approvals for Empaveli for two new indications and a lucrative royalty deal with Sobi enhance future revenue potential and bolster the company's balance sheet. With solid cash reserves and projected narrowing losses, Apellis is positioned for improved financial performance in the coming years.

The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.